Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Decreases By 91.8%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totaling 182,492 shares, a drop of 91.8% from the March 15th total of 2,231,716 shares. Based on an average daily volume of 58,298 shares, the days-to-cover ratio is presently 3.1 days. Approximately 3.5% of the shares of the company are short sold.

Xilio Therapeutics Price Performance

Shares of NASDAQ:XLO opened at $8.51 on Friday. The business’s 50 day moving average price is $7.92 and its 200-day moving average price is $9.42. The firm has a market capitalization of $49.19 million, a PE ratio of -1.55 and a beta of -0.15. Xilio Therapeutics has a 1 year low of $6.47 and a 1 year high of $16.52.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.68) by $0.83. The firm had revenue of $13.69 million for the quarter, compared to analyst estimates of $10.90 million. Xilio Therapeutics had a negative return on equity of 393.01% and a negative net margin of 80.05%. As a group, analysts expect that Xilio Therapeutics will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Xilio Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XLO. Frazier Life Sciences Management L.P. purchased a new position in shares of Xilio Therapeutics during the 4th quarter worth $3,787,000. Bain Capital Life Sciences Investors LLC raised its holdings in shares of Xilio Therapeutics by 61.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock valued at $4,720,000 after buying an additional 2,805,869 shares during the period. Empery Asset Management LP purchased a new stake in shares of Xilio Therapeutics in the 4th quarter valued at $757,000. Ghisallo Capital Management LLC purchased a new stake in shares of Xilio Therapeutics in the 4th quarter valued at $713,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Xilio Therapeutics in the 4th quarter valued at $109,000. Institutional investors and hedge funds own 54.29% of the company’s stock.

Wall Street Analysts Forecast Growth

XLO has been the subject of several research analyst reports. Wall Street Zen upgraded Xilio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xilio Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.